NASDAQ : VCEL

Vericel Corporation

$46.05 USD

$0.09 (0.2%)

Volume
497.86K
Average Volume
638.65K
Market Capitalization
$2.36B
P/E Ratio
95.94
Dividend Yield
0.00%
Price Target
$57.00
Year High
$49.32
Year Low
$28.95
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$5.04
Company Overview

NASDAQ

Dominick C. Colangelo

Biotechnology

Healthcare

VCEL

398

US

USD

https://vcel.com

617 588 5555

92346J108

0000887359

Liquidity Metrics

0.25

5.04

4.69

2.39

0.00

Sales & Valuation

$276.26M

7.70

6.34

47.50

0.97

Profitability

$0.32

$16.52M

7.91%

8.19%

6.91%

4.82%

P/E Metrics

95.94

0.40

0.40

Analyst Price Target & Rating

$57.00

$70.00

$46.00

Sell

2/5

14 Analysts

-19.21%

Financial Health Scores

10.86

6/9

$212.2M

$502.87M

$132.82M

$25.71M

Key Metrics (TTM)

$2.32B

7.58

60.35

5.04

6.91%

3.79%

1.03%

2.11%

$8.82

80 days

Company Executives
Name Title
Dominick C. Colangelo Chief Executive Officer, President & Director
Jonathan Hopper FRCSEd. Chief Medical Officer
Eric Burns Vice President of Finance & Investor Relations
Jonathan Siegal Principal Accounting Officer, Vice President & Corporate Controller
Joseph Anthony Mara Jr. Chief Financial Officer & Treasurer
Mike Gilligan Senior Vice President of Sales
Patrick J. Fowler Senior Vice President of Corporate Development & Strategy
Roland DeAngelis Chief Marketing Officer
Michael Halpin Chief Operating Officer
Sean C. Flynn Chief Legal Officer
Poll Results

No votes yet today — be the first to share your view!

About Vericel Corporation (NASDAQ:VCEL) Stock

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thick ... ness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.

Vericel Q2 Earnings Call Highlights

2026-07-30 17:04:55

Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

2026-07-30 12:54:01

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

2026-07-30 10:36:07

Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago.

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program

2026-07-30 07:55:00

Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Directors Authorizes $200 Million Share Repurchase Program Conference Call Today at 8:30am Eastern Time BURLINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2026.

Vericel Corporation $VCEL Shares Sold by Allspring Global Investments Holdings LLC

2026-07-21 03:08:12

Allspring Global Investments Holdings LLC trimmed its position in Vericel Corporation (NASDAQ: VCEL) by 3.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 678,003 shares of the biotechnology company's stock after selling 21,710 shares during the quarter. Allspring Global Investments Holdings

Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026

2026-07-16 08:30:00

BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second quarter 2026 financial results on Thursday, July 30, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests

2026-06-27 12:58:26

10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026. The sale represented 38% of Halpin's direct Common Stock holdings, reducing his direct stake from 26,248 to 16,248 shares, though he also has options.

Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026

2026-06-09 08:30:00

BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.

Frequently Asked Questions

What is the current Vericel Corporation (VCEL) stock price?

Vericel Corporation(NASDAQ:VCEL) stock price is $46.05 in the last trading session. During the trading session, VCEL stock reached the peak price of $49.32 while $28.95 was the lowest point it dropped to. The percentage change in VCEL stock occurred in the recent session was 0.2% while the dollar amount for the price change in VCEL stock was $0.09.

VCEL's industry and sector of operation?

The NASDAQ listed VCEL is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of VCEL?

Dominick C. Colangelo | Chief Executive Officer, President & Director
Jonathan Hopper FRCSEd. | Chief Medical Officer
Eric Burns | Vice President of Finance & Investor Relations
Jonathan Siegal | Principal Accounting Officer, Vice President & Corporate Controller
Joseph Anthony Mara Jr. | Chief Financial Officer & Treasurer

How many employees does VCEL have?

Number of VCEL employees currently stands at 398. VCEL operates from 64 Sidney Street, Cambridge, MA 02139, US.

Link for VCEL official website?

Official Website of VCEL is: https://vcel.com

How do I contact VCEL?

VCEL could be contacted at phone #617 588 5555 and can also be accessed through its website. VCEL operates from 64 Sidney Street, Cambridge, MA 02139, US.

How many shares of VCEL are traded daily?

The average number of VCEL shares traded daily for last 3 months was 638.65K.

What is the market cap of VCEL currently?

The market value of VCEL currently stands at $2.36B with its latest stock price at $46.05